AFP and liver cancer: Although 30%–40% of primary liver cancer is negative for AFP (29), it is still a sensitive tumor marker for the detection of HCC and a useful predictive factor due to its specificity for patient survival after locoregional or systemic treatment in HCC (30, 31).